ADCYAP1 and Parkinson disease: PACAP neuroprotective capacity has also been demonstrated in models of Parkinson’s disease (PD) induced by 1-methyl-4-phenylpyridinium ion (MPP+); (Chung et al., 2005; Deguil et al., 2010), 6-hydroxy-dopamine (6-OHDA) (Takei et al., 1998; Reglodi et al., 2004) or rotenone (Wang et al., 2005) and in models of Alzheimer’s disease (AD) induced by beta-amyloid protein (Frechilla et al., 2001; Onoue et al., 2002; Rat et al., 2011; Brown et al., 2013).